CSBR: championsoncology.com Company Value to Net Income

Champions Oncology, Inc. - graphic logo of issuer CSBR

This daily price chart for Champions Oncology (CSBR) with the -60.10 indicator highlights the macro-resilience of a business whose oncology drug development revenues are minimally subject to cyclicality. Management aims to increase the number of alliances with the pharmaceutical sector and implement advanced analysis systems. Financial stability relies on the demand for tumor IT models among industry behemoths, while the company closely monitors expenses during periods of client budget revisions.

Price to Earnings Ratio: Champions Oncology Corp (CSBR) for 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Champions Oncology Inc (CSBR)

Summary company analysis:CSBR Champions Oncology, Inc.
Flagship merchandise of Champions Oncology, Inc.

To assess the credit quality of Champions Oncology (CSBR), the analyst compares the business's market value with its actual ability to generate net profit, a trend captured by the price-to-earnings (P/E) multiple. Amid intense competition with AI platforms, this indicator measures the scalability premium of personalized therapy, where a rising ratio signals market confidence in the company's expansion, while a decline reflects risks of a slowdown in niche capture.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|ACTU: Price to Earnings Ratio|Citius Oncology, Inc. - Market Price to Net Income Ratio|HURA (TuHURA Biosciences) - Price to Earnings Ratio|TARA: Market Price to Net Income Ratio|Price to Earnings Ratio FATE|WHWK: Company Value to Net Income|Price to Earnings Ratio TCRX (TScan Therapeutics Inc)|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV